|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MCM10 |
Gene summary for MCM10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MCM10 | Gene ID | 55388 |
| Gene name | minichromosome maintenance 10 replication initiation factor | |
| Gene Alias | CNA43 | |
| Cytomap | 10p13 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q7L590 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55388 | MCM10 | P2T-E | Human | Esophagus | ESCC | 7.94e-07 | 2.26e-01 | 0.1177 |
| 55388 | MCM10 | P4T-E | Human | Esophagus | ESCC | 8.00e-03 | 1.26e-01 | 0.1323 |
| 55388 | MCM10 | P5T-E | Human | Esophagus | ESCC | 4.17e-05 | 1.72e-01 | 0.1327 |
| 55388 | MCM10 | P16T-E | Human | Esophagus | ESCC | 7.90e-03 | 1.30e-01 | 0.1153 |
| 55388 | MCM10 | P21T-E | Human | Esophagus | ESCC | 8.40e-04 | 1.38e-01 | 0.1617 |
| 55388 | MCM10 | P24T-E | Human | Esophagus | ESCC | 8.40e-04 | 1.85e-01 | 0.1287 |
| 55388 | MCM10 | P31T-E | Human | Esophagus | ESCC | 9.44e-07 | 2.11e-01 | 0.1251 |
| 55388 | MCM10 | P32T-E | Human | Esophagus | ESCC | 4.41e-07 | 1.74e-01 | 0.1666 |
| 55388 | MCM10 | P37T-E | Human | Esophagus | ESCC | 4.27e-06 | 2.10e-01 | 0.1371 |
| 55388 | MCM10 | P52T-E | Human | Esophagus | ESCC | 8.56e-12 | 2.50e-01 | 0.1555 |
| 55388 | MCM10 | P76T-E | Human | Esophagus | ESCC | 1.78e-03 | 1.21e-01 | 0.1207 |
| 55388 | MCM10 | P79T-E | Human | Esophagus | ESCC | 1.96e-05 | 2.15e-01 | 0.1154 |
| 55388 | MCM10 | P83T-E | Human | Esophagus | ESCC | 3.53e-13 | 6.07e-01 | 0.1738 |
| 55388 | MCM10 | P91T-E | Human | Esophagus | ESCC | 5.34e-06 | 6.81e-01 | 0.1828 |
| 55388 | MCM10 | P107T-E | Human | Esophagus | ESCC | 8.98e-03 | 1.18e-01 | 0.171 |
| 55388 | MCM10 | P130T-E | Human | Esophagus | ESCC | 3.89e-12 | 4.56e-01 | 0.1676 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
| GO:00062612 | Esophagus | ESCC | DNA-dependent DNA replication | 100/8552 | 151/18723 | 2.61e-07 | 3.94e-06 | 100 |
| GO:00062701 | Esophagus | ESCC | DNA replication initiation | 27/8552 | 34/18723 | 6.01e-05 | 4.62e-04 | 27 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MCM10 | SNV | Missense_Mutation | c.835N>G | p.Gln279Glu | p.Q279E | Q7L590 | protein_coding | deleterious(0) | possibly_damaging(0.467) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| MCM10 | SNV | Missense_Mutation | novel | c.871N>A | p.Glu291Lys | p.E291K | Q7L590 | protein_coding | deleterious(0.03) | benign(0.043) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| MCM10 | SNV | Missense_Mutation | c.1952N>G | p.Leu651Arg | p.L651R | Q7L590 | protein_coding | tolerated(0.15) | possibly_damaging(0.596) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD | |
| MCM10 | SNV | Missense_Mutation | c.224N>T | p.Ala75Val | p.A75V | Q7L590 | protein_coding | deleterious(0.01) | benign(0.297) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MCM10 | SNV | Missense_Mutation | c.1716G>A | p.Met572Ile | p.M572I | Q7L590 | protein_coding | tolerated(0.33) | benign(0.01) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MCM10 | SNV | Missense_Mutation | c.839N>A | p.Ile280Asn | p.I280N | Q7L590 | protein_coding | deleterious(0) | possibly_damaging(0.594) | TCGA-AO-A1KT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD | |
| MCM10 | SNV | Missense_Mutation | rs764318577 | c.1874N>T | p.Thr625Met | p.T625M | Q7L590 | protein_coding | tolerated(0.31) | benign(0.025) | TCGA-C8-A12K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MCM10 | insertion | Nonsense_Mutation | novel | c.2574_2575insCTCATGAAAACAAATAAGTCTCATGAGATCTGATGGTTTTAT | p.Glu858_Thr859insLeuMetLysThrAsnLysSerHisGluIleTerTrpPheTyr | p.E858_T859insLMKTNKSHEI*WFY | Q7L590 | protein_coding | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | ||
| MCM10 | insertion | Frame_Shift_Ins | novel | c.1354_1355insTTTTTGTTATAGCCATTGTAGTAGGTGTGAAGAGGTACTTCTT | p.Glu452ValfsTer43 | p.E452Vfs*43 | Q7L590 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MCM10 | SNV | Missense_Mutation | novel | c.187G>A | p.Glu63Lys | p.E63K | Q7L590 | protein_coding | tolerated(0.06) | benign(0.205) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |